Barrow Neurological Institute
Barrow Neurological Institute
Phoenix, Arizona, United States50 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-10-07 | NCT06847321 | |
| Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07322003 | |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 3 | 2026-10-06 | NCT07174310 | |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06132893 | |
| Alzheimer's Disease Neuroimaging Initiative 4 | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Pick disease, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Enrolling by invitation | Not stated | 2026-09-29 | NCT05617014 | |
| Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY | Arterial Occlusive Diseases, Cognition Disorders, Cognitive Dysfunction, Hemorrhage, Intracranial Hemorrhages, Leukoencephalopathies, Mild Cognitive Impairment, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, cognitive disorder, dementia, intracerebral hemorrhage, intracranial arterial disease, intracranial arteriosclerosis, ischemic stroke, nervous system disorder, psychiatric disorder, stroke disorder, subarachnoid hemorrhage, vascular dementia, vascular disorder | Recruiting | Not stated | 2026-09-14 | NCT04916210 | |
| The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms | Aneurysm, Bites and Stings, Chemically-Induced Disorders, Fusiform Aneurysm, Saccular Aneurysm, brain aneurysm, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hemorrhagic stroke, injury, intracranial arterial disease, nervous system disorder, poisoning, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-09-09 | NCT07143019 | |
| Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Active, not recruiting | Phase 4 | 2026-09-09 | NCT05232929 | |
| Parkinson's Foundation PD GENEration Genetic Registry | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2026-09-08 | NCT04994015 | |
| A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Active, not recruiting | Phase 2 | 2026-09-04 | NCT04777331 | |
| PREVENT ALL ALS Study | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Not stated | 2026-08-24 | NCT06581861 | |
| ASSESS ALL ALS Study | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Not stated | 2026-08-24 | NCT06578195 | |
| Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy | Spinal Curvatures, bone disorder, central nervous system disorder, motor neuron disorder, musculoskeletal system disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, scoliosis, spinal cord disorder, spinal muscular atrophy, vertebral column disorder | Recruiting | Not applicable | 2026-08-19 | NCT05866419 | |
| GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 2 | 2026-08-10 | NCT05686551 | |
| Study of COYA 302 for the Treatment of ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 / Phase 3 | 2026-08-06 | NCT07161999 | |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-07-29 | NCT05269004 | |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, anosmia, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2026-07-27 | NCT04477785 | |
| HEALEY ALS Platform Trial - Master Protocol | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-21 | NCT04297683 | |
| A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD) | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 / Phase 2 | 2026-07-20 | NCT07282847 | |
| A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) | Abnormalities, Multiple, Alzheimer disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Down syndrome, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, chromosomal disorder, cognitive disorder, dementia, hereditary disease, intellectual disability, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 1 / Phase 2 | 2026-07-10 | NCT05462106 | |
| Troriluzole in Adult Participants With Spinocerebellar Ataxia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Machado-Joseph disease, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Spinocerebellar Ataxias, Spinocerebellar Degenerations, Spinocerebellar ataxia 8, atactic disorder, non-human animal, brain disorder, cardiac arrest, cardiovascular disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, heart disorder, hereditary disease, inherited neurodegenerative disorder, nervous system disorder, neurodegenerative disease, spinal cord disorder, spinocerebellar ataxia 7, spinocerebellar ataxia type 1, spinocerebellar ataxia type 10, spinocerebellar ataxia type 2, spinocerebellar ataxia type 6, spinocerebellar ataxia type 8 | Active, not recruiting | Phase 3 | 2026-06-24 | NCT03701399 | |
| A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information | Bone Diseases, Developmental, Bone Diseases, Endocrine, Dwarfism, bone disorder, brain disorder, central nervous system disorder, endocrine system disorder, hypopituitarism, hypothalamic disorder, musculoskeletal system disorder, nervous system disorder, pituitary dwarfism, pituitary gland disorder | Enrolling by invitation | Not stated | 2026-06-12 | NCT05718570 | |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, generalized myasthenia gravis, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-09 | NCT06106672 | |
| Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population | Ear Diseases, Hearing Loss, Bilateral, Hearing Loss, Sensorineural, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, nervous system disorder, otorhinolaryngologic disease | Active, not recruiting | Not applicable | 2026-06-03 | NCT06293482 | |
| [18F]PI-2620 Phase 3 Histopathological Study | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-05-22 | NCT05641688 |